There is an avalanche of biomedical data generation and a parallel expansion in
computational capabilities to analyze and make sense of these data. Starting with genome …

The data‐independent acquisition mass spectrometry (DIA‐MS) has rapidly evolved as a
powerful alternative for highly reproducible proteome profiling with a unique strength of …

Parkinson's disease (PD) is a growing burden worldwide, and there is no reliable biomarker
used in clinical routines to date. Cerebrospinal fluid (CSF) is routinely collected in patients …

The utility of the urinary proteome in infectious diseases remains unclear. Here, we analyzed
the proteome and metabolome of urine and serum samples from patients with COVID-19 …

There are multiple reasons why the next generation of biological and medical studies
require increasing numbers of samples. Biological systems are dynamic, and the effect of a …

Biomarkers are assayed to assess biological and pathological status. Recent advances in
high-throughput proteomic technology provide opportunities for developing next generation …

Almost 2 decades after linking LRRK2 to Parkinson's disease, a vibrant research field has
developed around the study of this gene and its protein product. Recent studies have begun …

Introduction Biological fluids are routine samples for diagnostic testing and monitoring.
Blood samples are typically measured because of their moderate invasive collection and …

Prostate cancer is the second most frequently diagnosed non-skin cancer in men worldwide.
Patient outcomes are remarkably heterogeneous and the best existing clinical prognostic …

Proteomics and metabolomics are two emerging fields that hold promise to shine light on the
molecular mechanisms causing neurodegenerative diseases. Research in this area may …